Systemic Leukocyte-Directed siRNA Delivery Revealing Cyclin D1 as an Anti-Inflammatory Target
Top Cited Papers
- 1 February 2008
- journal article
- other
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 319 (5863) , 627-630
- https://doi.org/10.1126/science.1149859
Abstract
Cyclin D1 (CyD1) is a pivotal cell cycle–regulatory molecule and a well-studied therapeutic target for cancer. Although CyD1 is also strongly up-regulated at sites of inflammation, its exact roles in this context remain uncharacterized. To address this question, we developed a strategy for selectively silencing CyD1 in leukocytes in vivo. Targeted stabilized nanoparticles (tsNPs) were loaded with CyD1–small interfering RNA (siRNA). Antibodies to β7 integrin (β7 I) were then used to target specific leukocyte subsets involved in gut inflammation. Systemic application of β7 I-tsNPs silenced CyD1 in leukocytes and reversed experimentally induced colitis in mice by suppressing leukocyte proliferation and T helper cell 1 cytokine expression. This study reveals CyD1 to be a potential anti-inflammatory target, and suggests that the application of similar modes of targeting by siRNA may be feasible in other therapeutic settings.Keywords
This publication has 21 references indexed in Scilit:
- Utilizing RNA interference to enhance cancer drug discoveryNature Reviews Drug Discovery, 2007
- Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNAProceedings of the National Academy of Sciences, 2007
- Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1Proceedings of the National Academy of Sciences, 2007
- RUNNING INTERFERENCE: Prospects and Obstacles to Using Small Interfering RNAs as Small Molecule DrugsAnnual Review of Biomedical Engineering, 2006
- Targeted Delivery of Antisense Oligodeoxynucleotide and Small Interference RNA into Lung Cancer CellsMolecular Pharmaceutics, 2006
- Progress towards in Vivo Use of siRNAsMolecular Therapy, 2006
- Differential Regulation of D-Type Cyclins in the Mouse IntestineCell Cycle, 2005
- Potent and persistent in vivo anti-HBV activity of chemically modified siRNAsNature Biotechnology, 2005
- Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptorsNature Biotechnology, 2005
- The ?7 integrins in mucosal homing and retentionSeminars in Immunology, 1995